Page last updated: 2024-11-11

reparixin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

reparixin: inhibits CXCR1 to prevent polymorphonuclear cell recruitment [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9838712
CHEMBL ID191413
CHEBI ID177765
SCHEMBL ID1884299
MeSH IDM0473107

Synonyms (48)

Synonym
CHEBI:177765
(2r)-2-[4-(2-methylpropyl)phenyl]-n-methylsulonylpropanamide
2-(4-isobutylphenyl)propionylmethanesulfonamide
reparixin
repertaxin
df 1681y
df-1681y
df1681y
reparixin [inn]
n-[(r)-2-(4-isobutyl-phenyl)-propionyl]-methanesulfonamide
bdbm50169045
(r)-2-(4-isobutylphenyl)-n-(methylsulfonyl)propanamide
266359-83-5
D08984
reparixin (usan/inn)
CHEMBL191413 ,
dtxsid6046509 ,
cas-266359-83-5
tox21_112272
dtxcid4026509
SCHEMBL1884299
HY-15251
CS-1379
(2r)-2-(4-(2-methylpropyl)phenyl)-n-methylsulfonylpropanamide
reparixin [usan:inn]
unii-u604e1nb3k
benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)-, (alphar)-
benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)- (alphar)-
u604e1nb3k ,
S8640
benzeneacetamide, .alpha.-methyl-4-(2-methylpropyl)-n-(methylsulfonyl)-, (.alpha.r)-
reparixin [mart.]
reparixin [who-dd]
reparixin [usan]
gtpl8498
(2r)-2-[4-(2-methylpropyl)phenyl]-n-methylsulfonylpropanamide
AC-32023
mfcd18633292
AKOS027250779
DB12614
266359-83-5 (free base)
EX-A2461
BS-16754
Q27088533
BCP10635
CCG-267282
repertaxin;df 1681y
reparixin (repertaxin)

Research Excerpts

Overview

Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients.

ExcerptReferenceRelevance
"Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients."( Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Bertuzzi, F; Daffonchio, L; Golab, K; Gustafsson, B; Liew, A; Lundgren, T; Maffi, P; Piemonti, L; Rafael, E; Ruffini, PA; Saudek, F; Shaw, JAM; Tufveson, G; Witkowski, P, 2020
)
2
"Reparixin is a small molecule, allosteric noncompetitive inhibitor of CXCR1 and CXCR2 chemokine receptors involved in inflammation."( Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Flemming, JM; Marsh, DR, 2011
)
1.09
"Reparixin is a recently described inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation."( Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.
Bertini, R; Cavalieri, B; Di Giulio, AM; Gorio, A; Madaschi, L; Marfia, G; Zadra, G, 2007
)
2.5

Treatment

Reparixin treatment significantly decreased TC cell survival, proliferation, Epithelial-to-Mesenchymal Transition (EMT) and stemness. Pre-treatment with reparIXin reduced the motor deficits observed in this model of ischemia and reperfusion.

ExcerptReferenceRelevance
"Reparixin treatment significantly decreased TC cell survival, proliferation, Epithelial-to-Mesenchymal Transition (EMT) and stemness."( Multiple anti-tumor effects of Reparixin on thyroid cancer.
Allegretti, M; De Pizzol, M; Liotti, F; Melillo, RM; Prevete, N, 2017
)
1.46
"Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and reperfusion. "( Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.
Barcelos, Lda S; Campos, AC; Coelho, FM; Rachid, MA; Rodrigues, DH; Sousa, LF; Teixeira, AL; Teixeira, MM, 2013
)
0.72
"Treatment with reparixin or DF2162 (allosteric inhibitors of CXCR1/CXCR2) decreased neutrophil recruitment, an effect that was associated with marked inhibition of neutrophil adhesion."( The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.
Amaral, FA; Bertini, R; Coelho, FM; Costa, VV; Pinho, V; Rodrigues, DH; Sachs, D; Silva, TA; Souza, DG; Teixeira, AL; Teixeira, MM; Vieira, AT, 2008
)
0.69
"Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells."( Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.
Bertini, R; Cavalieri, B; Di Giulio, AM; Gorio, A; Madaschi, L; Marfia, G; Zadra, G, 2007
)
2.12

Pharmacokinetics

ExcerptReferenceRelevance
" The assay was validated for specificity, recovery, carryover and sample stability under various storage conditions; it was also successfully applied to measure drug concentrations collected from a pharmacokinetic study in rats."( Simultaneous quantification of reparixin and paclitaxel in plasma and urine using ultra performance liquid chromatography-tandem mass spectroscopy (UHPLC-MS/MS): Application to a preclinical pharmacokinetic study in rats.
Alrushaid, S; Davies, NM; Gu, X; Lakowski, TM; Malhi, S; Stesco, N, 2017
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
" To examine an alternative approach of integrin-based anti-osteosacoma strategy, acurhagin-C, a Glu-Cys-Asp (ECD)-disintegrin, was isolated and evaluated for its application in combination with two potent inhibitors of basic fibroblast growth factor (bFGF) and interleukin-8 (IL-8)."( Synergistic suppression of a disintegrin acurhagin-C in combination with AZD4547 and reparixin on terminating development for human osteosarcoma MG-63 cell.
Chiang, TB; Shih, CH; Wang, WJ, 2017
)
0.68

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency26.60860.000811.382244.6684AID686978
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.74000.000214.376460.0339AID720692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)0.00310.00102.022710.0000AID248424; AID707880
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.03540.00000.30296.0130AID248424; AID707876; AID707879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 1Homo sapiens (human)
immune responseC-X-C chemokine receptor type 1Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 1Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID707908Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID297155Inhibition of CXCL8-induced cell migration in L1.2 cells expressing CXCR1 by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID657853Inhibition of CXCR2 in human polymorphonucleate cells assessed as inhibition of CXCL1-induced chemotaxis at 10'-8 M incubated for 15 mins prior to CXCL1-induction measured after 45 mins2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.
AID657857Elimination half life in Sprague-Dawley rat at 14 mg/kg, iv2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID707876Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID606366Noncompetitive inhibition of human CXCR1 assessed as inhibition of CXCL8-induced neutrophile chemotaxis at 10 nM2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Progress in structure based drug design for G protein-coupled receptors.
AID248424Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID657854Inhibition of CXCR1/2 in human polymorphonucleate cells assessed as inhibition of CXCL8-induced chemotaxis at 10'-8 M incubated for 15 mins prior to CXCL8-induction measured after 45 mins2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.
AID297154Inhibition of CXCL8-induced cell migration in L1.2 cells expressing wild type CXCR1 at up to 1000 nM by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID297156Inhibition of CXCL8-induced cell migration in L1.2 cells expressing Ile43Val CXCR1 mutant by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID707879Binding affinity to CXCR22012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID297153Inhibition of CXCL8-induced cell migration in L1.2 cells expressing wild type CXCR1 at 0.1 uM by chemotaxis assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID707880Binding affinity to CXCR12012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID1346925Human CXCR1 (Chemokine receptors)2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
AID1346826Human CXCR2 (Chemokine receptors)2004Proceedings of the National Academy of Sciences of the United States of America, Aug-10, Volume: 101, Issue:32
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (25.37)29.6817
2010's35 (52.24)24.3611
2020's15 (22.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.96 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index51.48 (26.88)
Search Engine Supply Index1.96 (0.95)

This Compound (37.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.71%)5.53%
Reviews3 (4.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]